Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514820 | 0.86 | MTNR1A (0.61) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL19007377 | 0.84 | DRD2 (0.46) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL30773715 | 0.84 | DRD2 (0.52) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL28527177 | 0.83 | DRD2 (0.45) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL19007375 | 0.83 | DRD2 (0.45) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL1972529 | 0.83 | MTNR1A (0.54) | CA12CA1CA2CA9MTNR1A | |
| SCHEMBL22642707 | 0.83 | DRD2 (0.51) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL3922652 | 0.83 | BCHE (0.47) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL24936189 | 0.82 | KCNH2 (0.50) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL30522714 | 0.82 | KCNH2 (0.50) | DRD2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| US-11123326-B2 | CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123326-B2 | CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3325468-B1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | LILLY CO ELI (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20180369202-A1 | CHK1/2 Inhibitors for Use in the Treatment of Neuroblastomas and/or Soft Tissue Sarcomas | ELI LILLY AND COMPANY | 2018-12-27 | — | — | US | disclosed |
| EP-2379532-B1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | LILLY CO ELI (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2379532-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369202-A1 | CHK1/2 Inhibitors for Use in the Treatment of Neuroblastomas and/or Soft Tissue Sarcomas | CHEK1, CHEK2, PLK1 | DRD2 4489/4885CA12 3940/4885CA1 4551/4885 |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PLK1 | DRD2 4461/4885CA12 4459/4885CA1 3809/4885 |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | CHEK1, CHEK2, PLK1 | DRD2 4306/4885CA12 3562/4885CA1 4230/4885 |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | CHEK1, CHEK2, MRE11 | DRD2 4727/4885CA12 4073/4885CA1 4533/4885 |
| US-11123326-B2 | CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma | CHEK1, CHEK2, TOP2A | DRD2 4313/4885CA12 3075/4885CA1 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.